2008
Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
Tamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Hirsch I, Huang E, Kollman C, Kowalski A, Laffel L, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal Of Medicine 2008, 359: 1464-1476. PMID: 18779236, DOI: 10.1056/nejmoa0805017.Peer-Reviewed Original ResearchConceptsYears of ageContinuous glucose monitoringContinuous monitoring groupPatients 25 yearsGlycated hemoglobin levelsType 1 diabetesHemoglobin levelsGlucose monitoringStudy groupControl groupType 1 diabetes mellitusMulticenter clinical trialBetween-group differencesHemoglobin outcomesYounger patientsDiabetes mellitusGlycemic controlIntensive therapyPrimary outcomeSevere hypoglycemiaClinical trialsIntensive treatmentAge groupsBlood glucose metersType 1
1999
Serum IGF‐I and IGFBP‐3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours
Weinzimer S, Homan S, Ferry R, Moshang T. Serum IGF‐I and IGFBP‐3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours. Clinical Endocrinology 1999, 51: 339-345. PMID: 10469014, DOI: 10.1046/j.1365-2265.1999.00804.x.Peer-Reviewed Original ResearchConceptsIGF-binding protein-3Hypothalamic/chiasmatic gliomaIGFBP-3 levelsGrowth hormone deficiencyBody mass indexPrimitive neuroectodermal tumorHypothalamic-chiasmatic gliomaProvocative GH testingIGFBP-3 concentrationsIGF-I levelsGH deficiencyGH testingHormone deficiencySerum IGFBrain tumorsPubertal stageTumor typesLower IGFBP-3 levelsNormal IGF-1 levelsLow IGF-I levelsGrowth factor insulin-like growth factorInsulin-like growth factorIGF-1 levelsRetrospective case reviewBone age delay